Abstract
Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepines and neurosteroids but potentiating GABAA receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of benzodiazepines. Gabapentin is an antiepileptic drug structurally related to GABA but with a mechanism of action that is still unclear. Methods: Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of gabapentin was first evaluated. In a second part, the effects of both drugs were evaluated in a test retest procedure in the FPT. Results: Gabapentin, for non sedative doses, increased significantly the number of punished passages in the FPT as did etifoxine. In the test -retest procedure, etifoxine (40 and 50 mg.kg) increased the number of shocks accepted by the animal as compared with benzodiazepine. The same effect was observed with gabapentin (32 and 64 mg/kg) with an increase in retested mice responding during the second trial. However, the effect was smaller than that achieved with DOI (a 5-HT2A agonist). Those results are of importance as it was the first time that GABAergic like ligands respond, even weakly, in experienced mice in the FPT. Whether this effect is due to stress or anxiety is open to discussion.
Keywords: Etifoxine, gabapentin, four-plate test, test-retest procedure, stress, anxiety, mice, benzodiazepine, Xenopus oocytes, GABAAR, neocortex, hypothalamus, diazepam, Flumazenil
Current Psychopharmacology
Title: Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin
Volume: 1
Author(s): Michel Bourin and Martine Hascoet
Affiliation:
Keywords: Etifoxine, gabapentin, four-plate test, test-retest procedure, stress, anxiety, mice, benzodiazepine, Xenopus oocytes, GABAAR, neocortex, hypothalamus, diazepam, Flumazenil
Abstract: Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepines and neurosteroids but potentiating GABAA receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of benzodiazepines. Gabapentin is an antiepileptic drug structurally related to GABA but with a mechanism of action that is still unclear. Methods: Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of gabapentin was first evaluated. In a second part, the effects of both drugs were evaluated in a test retest procedure in the FPT. Results: Gabapentin, for non sedative doses, increased significantly the number of punished passages in the FPT as did etifoxine. In the test -retest procedure, etifoxine (40 and 50 mg.kg) increased the number of shocks accepted by the animal as compared with benzodiazepine. The same effect was observed with gabapentin (32 and 64 mg/kg) with an increase in retested mice responding during the second trial. However, the effect was smaller than that achieved with DOI (a 5-HT2A agonist). Those results are of importance as it was the first time that GABAergic like ligands respond, even weakly, in experienced mice in the FPT. Whether this effect is due to stress or anxiety is open to discussion.
Export Options
About this article
Cite this article as:
Bourin Michel and Hascoet Martine, Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010002
DOI https://dx.doi.org/10.2174/2211556011201010002 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Phosphodiesterase 7A: A New Therapeutic Target for Alleviating Chronic Inflammation?
Current Pharmaceutical Design Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry Antioxidant Capacity, Phytochemical Analysis and Identification of Active Compounds in Anchomanes difformis
The Natural Products Journal Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Preface
Current Pharmaceutical Design 5-HT7 Receptors
Current Drug Targets - CNS & Neurological Disorders Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Heart Rate Variability Based Prediction of Personalized Drug Therapeutic Response: The Present Status and the Perspectives
Current Topics in Medicinal Chemistry PET Imaging in Clinical Drug Abuse Research
Current Pharmaceutical Design Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery The Patch Clamp Technique in Ion Channel Research
Current Pharmaceutical Biotechnology Nanotechnology and Drug Delivery: Getting There is Only Half of the Challenge! (Commentary)
CNS & Neurological Disorders - Drug Targets Heat Shock Proteins and Ion Channels. Functional Interactions and Therapeutic Consequences
Current Pharmaceutical Biotechnology Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging